Tenosynovial Giant Cell Tumor
📧 Sign up to get email alerts when something new happens for Tenosynovial Giant Cell Tumor.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-08-27FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) from Daiichi Sankyo Inc. This notice indicates an approved …
-
FDA approval · 2025-02-14FDA Approved: ROMVIMZA — Original Application (Deciphera Pharmaceuticals, LLC)
The FDA approved ROMVIMZA (vimseltinib) under an Original Application for tenosynovial giant cell tumor, establishing a new treatment option…
-
FDA approval · 2025-01-03FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
This FDA notice documents a supplemental application approval for TURALIO (pexidartinib hydrochloride) submitted by Daiichi Sankyo Inc. The …
-
FDA approval · 2023-11-16FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) filed by Daiichi Sankyo Inc., resulting in updated regulato…
-
FDA approval · 2023-04-17FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
The FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) by Daiichi Sankyo Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-10-14FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
The FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) by Daiichi Sankyo Inc. The action pertains to treatment…
-
FDA approval · 2022-10-06FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
The FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) submitted by Daiichi Sankyo Inc., resulting in updated …
-
FDA approval · 2022-07-14FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) filed by Daiichi Sankyo Inc., enabling changes to the drug'…
-
FDA approval · 2021-10-20FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
The FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) from Daiichi Sankyo Inc.
-
FDA approval · 2020-12-16FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
The FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) submitted by Daiichi Sankyo Inc. This action pertains t…
-
FDA approval · 2020-08-04FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
The FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) submitted by Daiichi Sankyo Inc.
-
FDA approval · 2020-04-17FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) from Daiichi Sankyo Inc., expanding the regulatory status f…
-
FDA approval · 2020-04-10FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
FDA approves a supplemental application for TURALIO (PEXIDARTINIB HYDROCHLORIDE) from Daiichi Sankyo Inc.
-
FDA approval · 2019-11-19FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
The FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) submitted by Daiichi Sankyo Inc., updating the drug's l…
-
FDA approval · 2019-08-02FDA Approved: TURALIO — Original Application (Daiichi Sankyo Inc.)
The FDA approved TURALIO (pexidartinib hydrochloride) in support of the original NDA for the treatment of tenosynovial giant cell tumor (TGC…